Home » Novel Drug Stars in Phase III PAH Trial
Novel Drug Stars in Phase III PAH Trial
Macitentan, an investigational next-generation endothelin receptor antagonist for pulmonary arterial hypertension (PAH), met its efficacy endpoint and was well tolerated in a large clinical trial.
MedPage Today
MedPage Today
Upcoming Events
-
07May
-
14May
-
30May